Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

MorphoSys AG. (12/8/14). "Press Release: MorphoSys Presents Updated Phase 2 Clinical Results for MOR208 Monotherapy in NHL at American Society of Hematology Meeting. DLBCL and FL Identified as Particularly Promising Indications".

Organisations Organisation MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group MorphoSys (Group)
  Organisation 2 American Society of Hematology (ASH)
Products Product MOR208 (MorphoSys/Xencor, formerly XmAb5574)
  Product 2 clinical research
Persons Person Schottelius, Arndt (Kymab 201806 EVP RnD before MorphoSys 200812–201701 Chief Developm Officer before Genentech)
  Person 2 Gutjahr-Löser, Claudia (MC Services 201710– Managing Director before MorphoSys 2002–2017 + Cassiopeia + Deutsche Bank)
     


   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top